Significant studies indicate that Donanemab, a experimental monoclonal antibody , has the potential to lessen the progression of mild cognitive decline. This therapy focuses on removing amyloid https://socialmediainuk.com/story26613887/lecanemab-a-emerging-novel-cognitive-treatment